Online citations, reference lists, and bibliographies.
← Back to Search

Physicochemical And Immunological Characterization Of N,N,N-Trimethyl Chitosan-Coated Whole Inactivated Influenza Virus Vaccine For Intranasal Administration

N. Hagenaars, E. Mastrobattista, R. Verheul, Imke Mooren, H. Glansbeek, J. Heldens, H. V. D. Bosch, W. Jiskoot
Published 2009 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
PurposeThe purpose of this study was the development and physicochemical and immunological characterization of intranasal (i.n.) vaccine formulations of whole inactivated influenza virus (WIV) coated with N,N,N-trimethyl chitosan (TMC).MethodsSynthesized TMCs with a degree of quarternization of 15% (TMC15) or 37% (TMC37) were tested in vitro for their ability to decrease the transepithelial resistance (TEER) of an epithelial cell monolayer. TMC15- and TMC37-coated WIV (TMC15-WIV and TMC37-WIV) were characterized by zeta potential measurements, dynamic light scattering, electron microscopy and gel permeation chromatography. Mice were vaccinated i.n. with selected vaccine formulations and immunogenicity was determined by measuring serum hemagglutination inhibition (HI) and serum IgG, IgG1 and IgG2a/c titers. Also a pulse-chase study with TMCs in solution administered i.n. 2 h prior to WIV was performed. Protective efficacy of vaccination was determined by an aerosol virus challenge.ResultsTMC37 induced a reversible decrease in TEER, suggesting the opening of tight junctions, whereas TMC15 did not affect TEER. Simple mixing of (negatively charged) WIV with TMC15 or TMC37 resulted in positively charged particles with TMCs being partially bound. Intranasal immunization with TMC37-WIV or TMC15-WIV induced stronger HI, IgG, IgG1 and IgG2a/c titers than WIV alone. TMC37-WIV induced the highest immune responses. Both TMC15-WIV and TMC37-WIV provided protection against challenge, whereas WIV alone was not protective. Intranasal administration of TMC prior to WIV did not result in significant immune responses, indicating that the immunostimulatory effect of TMC is primarily based on improved i.n. delivery of WIV.ConclusionsCoating of WIV with TMC is a simple procedure to improve the delivery and immunogenicity of i.n. administered WIV and may enable effective i.n. vaccination against influenza.
This paper references
Comparison of Serology and Reactogenicity between Influenza Subunit Vaccines and Whole Virus or Split Vaccines
W. Beyer (1998)
Synthesis, characterization and in vitro biological properties of O-methyl free N,N,N-trimethylated
R. J. Verheul (2008)
Mucosal Delivery of Inactivated Influenza Vaccine Induces B-Cell-Dependent Heterosubtypic Cross-Protection against Lethal Influenza A H5N1 Virus Infection
T. Tumpey (2001)
Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs
F. Geeraedts (2008)
Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system.
M. Amidi (2006)
induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice
J. Jaworska Minne (2003)
Synthesis, characterization and in vitro biological properties of O-methyl free N,N,N-trimethylated chitosan.
R. Verheul (2008)
synthetic receptors for future medicine
J. P. Schillemans (2006)
Chitosans as absorption enhancers of poorly absorbable drugs. 3: Influence of mucus on absorption enhancement.
N. G. Schipper (1999)
Live attenuated versus inactivated influenza vaccine in infants and young children.
R. Belshe (2007)
Synthesis, characterization and cytotoxicity of poly(ethylene glycol)-graft-trimethyl chitosan block copolymers.
S. Mao (2005)
Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs.
S. M. van der Merwe (2004)
Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses.
X. Lu (2006)
Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
N. Hagenaars (2008)
Effect of chitosan structure properties and molecular weight on the intranasal absorption of tetramethylpyrazine phosphate in rats.
Dan Mei (2008)
N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.
M. Amidi (2007)
The annual production cycle for influenza vaccine.
C. Gerdil (2003)
Preparation and NMR characterization of highly substitutedN-trimethyl chitosan chloride
A. Sieval (1998)
Molecularly imprinted polymer particles: synthetic receptors for future medicine.
J. Schillemans (2006)
Chitosan as a novel nasal delivery system for vaccines.
L. Illum (2001)
Uptake and Cytotoxicity of Chitosan Molecules and Nanoparticles: Effects of Molecular Weight and Degree of Deacetylation
M. Huang (2004)
Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice.
I. M. van der Lubben (2003)
Chitosan chemistry and pharmaceutical perspectives.
M. Kumar (2004)
Uptake and Transport of PEG-Graft-Trimethyl-Chitosan Copolymer–Insulin Nanocomplexes by Epithelial Cells
S. Mao (2005)
Induction of cytotoxic T‐lymphocyte and antibody responses against highly pathogenic avian influenza virus infection in mice by inoculation of apathogenic H5N1 influenza virus particles inactivated with formalin
T. Sawai (2008)
Protective immune responses to meningococcal C conjugate vaccine after intranasal immunization of mice with the LTK63 mutant plus chitosan or trimethyl chitosan chloride as novel delivery platform
B. Baudner (2005)
Effective nasal influenza vaccine delivery using chitosan.
R. Read (2005)
Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice.
Ayato Takada (2003)
Effect of the degree of quaternisation of N-trimethyl chitosan chloride on absorption enhancement: in vivo evaluation in rat nasal epithelia.
J. Hamman (2002)
Superior Immunogenicity of Inactivated Whole Virus H5N1 Influenza Vaccine is Primarily Controlled by Toll-like Receptor Signalling
F. Geeraedts (2008)
Recent advances on chitosan-based micro- and nanoparticles in drug delivery.
S. Agnihotri (2004)
A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children.
P. Gross (1977)
The relationship between the absolute molecular weight and the degree of quaternisation of N-trimethyl chitosan chloride
D. Snyman (2002)
Chitosan for enhanced intestinal permeability: prospects for derivatives soluble in neutral and basic environments.
A. Kotzé (1999)
N-Trimethyl Chitosan Chloride as a Potential Absorption Enhancer Across Mucosal Surfaces: In Vitro Evaluation in Intestinal Epithelial Cells (Caco-2)
Awie R Kotzé (2004)
Diphtheria toxoid-containing microparticulate powder formulations for pulmonary vaccination: preparation, characterization and evaluation in guinea pigs.
M. Amidi (2007)
Effect of degree of quaternization of N-trimethyl chitosan chloride for enhanced transport of hydrophilic compounds across intestinal caco-2 cell monolayers.
M. Thanou (2000)
Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
B. Sayin (2008)
Chitosans as Absorption Enhancers for Poorly Absorbable Drugs. 1: Influence of Molecular Weight and Degree of Acetylation on Drug Transport Across Human Intestinal Epithelial (Caco-2) Cells
N. G. Schipper (2004)
Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination
Robert J. Garmise (2008)
A Non-Living Nasal Influenza Vaccine Can Induce Major Humoral and Cellular Immune Responses in Humans without the Need for Adjuvants
H. H. Samdal (2005)
Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future.
R. Mueller (2001)
Epidermal Powder Immunization Induces both Cytotoxic T-Lymphocyte and Antibody Responses to Protein Antigens of Influenza and Hepatitis B Viruses
D. Chen (2001)
Formulation of a dry powder influenza vaccine for nasal delivery
Robert J. Garmise (2008)
Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets.
A. Lipatov (2006)
Rational design of nasal vaccines.
B. Slütter (2008)
Influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells
N. G. Schipper (1996)
In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery.
Fu Chen (2008)
Chitosan and trimethyl chitosan chloride (TMC) as adjuvants for inducing immune responses to ovalbumin in mice following nasal administration.
Worawan Boonyo (2007)
Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection.
T. Moran (1999)
Chitosan as Scaffold Materials: Effects of Molecular Weight and Degree of Deacetylation
S. Hsu (2004)
Intranasal delivery of whole influenza vaccine prevents subsequent allergen‐induced sensitization and airway hyper‐reactivity in mice
A. Minne (2007)
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.
T. Mosmann (1983)
In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein
F. Chen (2008)
Transport of Chitosan Microparticles for Mucosal Vaccine Delivery in a Human Intestinal M-cell Model
I. M. van der Lubben (2002)
Cross-Protection against H5N1 Influenza Virus Infection Is Afforded by Intranasal Inoculation with Seasonal Trivalent Inactivated Influenza Vaccine
T. Ichinohe (2007)
Formulation and optimization of controlled release mucoadhesive tablets of atenolol using response surface methodology
B. Singh (2008)
Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice
A-O Hovden (2005)

This paper is referenced by
Intranasal Delivery of Influenza Subunit Vaccine Formulated with GEM Particles as an Adjuvant
V. Saluja (2009)
Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations.
S. Bal (2010)
Nano-adjuvanted polio vaccine: Preparation and characterization of chitosan and trimethylchitosan (TMC) nanoparticles loaded with inactivated polio virus and coated with sodium alginate
M. Tafaghodi (2014)
Development of an adjuvanted nanoparticle vaccine against influenza virus, an in vitro study
Kamonthip Rungrojcharoenkit (2020)
The construction of in vitro nasal cavity-mimic M-cell model, design of M cell-targeting nanoparticles and evaluation of mucosal vaccination by nasal administration
Xiaotong Yang (2020)
Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.
B. Slütter (2010)
Extensive N-methylation of chitosan: evaluating the effects of the reaction conditions by using response surface methodology
Tonimar D. A. Senra (2015)
Emerging Nanotechnology Approaches for Pulmonary Delivery of Vaccines
A. Goyal (2014)
Trimethyl Chitosan Nanoparticles Encapsulated Protective Antigen Protects the Mice Against Anthrax
A. Malik (2018)
H9N2 Influenza Whole Inactivated Virus Combined with Polyethyleneimine Strongly Enhances Mucosal and Systemic Immunity after Intranasal Immunization in Mice
T. Qin (2015)
Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen.
B. Slütter (2010)
The role of surface charge of ISCOMATRIX nanoparticles on the type of immune response generated against Leishmaniasis in BALB/c mice
A. Mehravaran (2014)
Antigen-adjuvant nanoconjugates for nasal vaccination: an improvement over the use of nanoparticles?
B. Slütter (2010)
Microneedle-Based Transcutaneous Immunisation in Mice with N-Trimethyl Chitosan Adjuvanted Diphtheria Toxoid Formulations
S. Bal (2010)
Small is beautiful: N-trimethyl chitosan-ovalbumin conjugates for microneedle-based transcutaneous immunisation.
S. Bal (2011)
Role of trimethylated chitosan (TMC) in nasal residence time, local distribution and toxicity of an intranasal influenza vaccine.
N. Hagenaars (2010)
Progress in chitosan-based vaccine delivery systems
F. Esmaeili (2010)
Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccination.
B. Slütter (2010)
Quaternary ammonium salts of chitosan. A critical overview on the synthesis and properties generated by quaternization
Bianca-Iustina Andreica (2020)
Molecular Vaccines
M. Giese (2014)
Biodegradable Polymeric Nanocarrier-Based Immunotherapy in Hepatitis Vaccination.
S. J. Hong (2018)
Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine.
N. Hagenaars (2009)
Immunity after Intranasal Immunization in Mice
T. Qin (2015)
Induction of respiratory immune responses in the chicken; implications for development of mucosal avian influenza virus vaccines
E. Geus (2012)
Chapter 5 Efficient induction of immune responses through intradermal vaccination with TMC containing antigen formulations
S. Bal (2010)
Chitosan based delivery systems for mucosal immunization against bovine herpesvirus 1 (BHV-1).
Merve Günbeyaz (2010)
Characterization of Nasal Cavity‐Associated Lymphoid Tissue in Ducks
H. Kang (2014)
The Application of Empirical Phase Diagrams to the Biophysical Characterization and Stabilization of Viral Vaccine Candidates
Julian M Kissmann (2010)
Comparison of PLA Microparticles and Alum as Adjuvants for H5N1 Influenza Split Vaccine: Adjuvanticity Evaluation and Preliminary Action Mode Analysis
W. Zhang (2013)
A step-by-step approach to study the influence of N-acetylation on the adjuvanticity of N,N,N-trimethyl chitosan (TMC) in an intranasal nanoparticulate influenza virus vaccine.
R. Verheul (2012)
Biodegradable particles as vaccine antigen delivery systems for stimulating cellular immune responses
V. Joshi (2013)
Foot and Mouth Disease virus-loaded fungal chitosan nanoparticles for intranasal administration: impact of formulation on physicochemical and immunological characteristics
F. Tajdini (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar